FDA approves higher dose version of weight loss drug Wegovy as Novo Nordisk tries to win back market share

Thread starter U.S. News
Start date Mar 19, 2026

U.S. News

Guest

Mar 19, 2026

The high-dose Wegovy helped patients with obesity lose an average 20.7% of their weight after 72 weeks in a phase three trial.

Continue reading...

You must log in or register to reply here.

Facebook X Bluesky LinkedIn Reddit Pinterest Tumblr WhatsApp Email Link

Thread Information

Title: FDA approves higher dose version of weight loss drug Wegovy as Novo Nordisk tries to win back market share

Prefix: N/A

Forum: USA News

Start date: Mar 19, 2026

Last reply date: Mar 19, 2026

Replies: 0

Thread Tags

Thread statistics

Created: U.S. News, Mar 19, 2026

Replies: 0

Views: 9

About Us

XenTR Lorem Ipsum has been the industry's standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type specimen book.

It is a long established fact that a reader will be distracted by the readable content of a page when looking at its layout.

Color picker

Search